Immune interference revisited: Impact of live-attenuated influenza vaccine prior to yellow fever vaccination

Vaccine ◽  
2022 ◽  
Author(s):  
Dana M. Blyth ◽  
Zhaodong Liang ◽  
Maya Williams ◽  
Clinton K. Murray
Vaccine ◽  
2020 ◽  
Vol 38 (52) ◽  
pp. 8286-8291
Author(s):  
Nicole P. Lindsey ◽  
Lori Perry ◽  
Marc Fischer ◽  
Tabitha Woolpert ◽  
Brad J. Biggerstaff ◽  
...  

2021 ◽  
pp. 135245852110063
Author(s):  
Caroline Papeix ◽  
Julie Mazoyer ◽  
Elisabeth Maillart ◽  
Caroline Bensa ◽  
Anne-Laure Dubessy ◽  
...  

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53–3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.


Vaccine ◽  
2011 ◽  
Vol 29 (16) ◽  
pp. 2887-2894 ◽  
Author(s):  
Melissa B. Pearce ◽  
Jessica A. Belser ◽  
Katherine V. Houser ◽  
Jacqueline M. Katz ◽  
Terrence M. Tumpey

Sign in / Sign up

Export Citation Format

Share Document